Cilengitide is an experimental anti-cancer drug that functions as an integrin inhibitor. Specifically, it targets αvβ3 and αvβ5 integrins, which are proteins involved in the processes of angiogenesis, tumor growth, and metastatic spread. By inhibiting these integrins, cilengitide aims to disrupt the blood supply to the tumor, thereby inhibiting its growth and spread.
